Clinical trial · Interventional
Crizotinib Continuation Clinical Study
CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES
NCT05160922CI-TRIAL-00106694active not recruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALCL | Anaplastic Large Cell Lymphoma | ALIAS | 0.90 |
| IMT | Inflammatory Myofibroblastic Tumor | ALIAS | 0.90 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| crizotinib | Drug | Crizotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- crizotinib
- description
- crizotinib oral treatment
- interventionNames
- Drug: crizotinib
Primary outcomes (2)
- measure
- Number of participants with adverse events leading to permanent discontinuation of study intervention
- timeFrame
- Baseline up to approximately 5 years
- description
- Safety data collection in this study will permit further characterization of the safety profile of crizotinib.
- measure
- Number of serious adverse events reported for all participants
- timeFrame
- Baseline up to approximately 5 years
- description
- Safety data collection in this study will permit further characterization of the safety profile of crizotinib.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
Show eligibility criteria text
Participants must meet the following key inclusion criteria to be eligible for enrollment into the study: 1. Any participant who is receiving crizotinib and deriving clinical benefit (as determined by their doctor) in a Crizotinib Study which is planned to close. 2. Participants must agree to follow the reproductive criteria as outlined in protocol. 3. No ongoing Grade ≥3 or intolerable Grade 2 AEs considered to be related to crizotinib treatment, except for those laboratory eligibility criteria described in Inclusion #4. 4. Adult Participants (≥18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days. Pediatric Participants (\<18 years): Adequate hepatic and bone marrow function. Stable renal function for at least 14 days. Exclusion Criteria Participants with any of the following characteristics/conditions will be excluded: 1. Female participants who are pregnant or breastfeeding. 2. Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.